The number of gout patients is rising, with an estimated 8.3 million American adults diagnosed with gout—but only 10 percent of them are being properly treated, according to the Gout & Uric Acid Education Society. To heighten awareness and knowledge about gout and to lead to earlier diagnosis and treatment, the society has released two new comprehensive kits to educate patients and provide consistent information for medical professionals. The release of the Take a Stand on Gout Patient Education Kit and Medical Professional Information Kit coincides with Gout Awareness Day, an annual commemoration on May 22 to call attention to the growing incidence of gout and to enhance knowledge so as to improve patient outcomes. Both kits provide new, substantial information about gout from specialists, who treat gout patients every day.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61805-gout-uric-acid-education-society-take-a-stand-on-gout-new-information-kits
The Gout & Uric Acid Education Society (GUAES) has added six new educational videos for patients and medical professionals to its library of popular educational videos on gout, highlighting the society’s most important takeaways from the recently released American College of Rheumatology (ACR) Guidelines on Gout Diagnosis and Treatment. Available under the patient and medical professional portals on www.GoutEducation.org, respectively, the latest videos emphasize the need for continuous communication between gout patients and their doctors about their unique treatment plan, to help prevent gout flares and long-term complications from this poorly understood form of inflammatory arthritis.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60699-gout-uric-acid-education-society-guaes-new-videos-on-acr-guidelines
InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate
More than 80,000 healthcare workers and their communities from across the country and around the world joined together in the Medline Pink Glove Dance for breast cancer online video competition. After a hard-fought dance battle, the online votes are in and Medline is pleased to name Geisinger Health System, Danville, Pa., as the winner. As a result, $25,000 will be donated to their charity of choice, the American Cancer Society, providing free transportation for treatment to central Pennsylvania breast cancer patients in need. Additionally, Medline and participating hospitals will donate another $1 million to the National Breast Cancer Foundation and various local breast cancer charities nationwide. More than $2.2 million has been donated through the campaign and Medline Foundation since 2005.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64450-medline-pink-glove-dance-video-competition-winners-breast-cancer-education
Phiten, the pioneer of AQUA-METAL™ materials and innovator of metal-infused technology, and professional baseball players C.J. Wilson, Josh Hamilton and J.B. Shuck have teamed up with Be The Match, the nonprofit organization dedicated to helping patients with blood cancers receive life-saving bone marrow and umbilical cord blood transplants. To support Be The Match and raise awareness of the national Be The Match Registry®, Phiten has designed a limited edition Phiten x Be The Match Tornado Necklace with sales benefiting the cause, and the three pro baseball players have been named Ambassadors of Hope by Be The Match.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64376-phiten-and-mlb-players-for-be-the-match-bone-marrow-donor-registry
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
The Asthma and Allergy Foundation of America (AAFA) and Teva Respiratory announced today the launch of a national awareness campaign – Know Your Count – aimed at raising awareness of the seriousness of asthma and educating asthma patients and caregivers about the importance of keeping track of the remaining doses in their rescue inhalers. The campaign features award-winning singer and actress, Kristin Chenoweth, who is speaking publicly for the first time about the impact her asthma has had on her professional career and busy lifestyle. For more information about the Know Your Count campaign, Kristin’s experience with asthma and to view an important public service announcement (PSA), visit www.KnowYourCount.com.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/65058-teva-respiratory-aafa-know-your-count-managing-asthma/
The quaint Irish village of Ballybucklebo is full of colorful characters and eccentric patients that two country doctors must tend to, but with love in the air each doctor has their hands, and hearts, full. NY Times bestselling author Patrick Taylor transports us back to the Ireland of the 1960s with his beloved Irish Country Books series. Find out more at http://us.macmillan.com/anirishcountrywedding/PatrickTaylor. Fiction, historical fiction
CVS Caremark (NYSE: CVS) announced today that it will stop selling cigarettes and other tobacco products at its more than 7,600 CVS/pharmacy stores across the U.S. by October 1, 2014, making CVS/pharmacy the first national pharmacy chain to take this step in support of the health and well-being of its patients and customers.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65510-cvs-caremark-to-stop-selling-tobacco-products-at-cvs-pharmacy-locations
Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced that its epilepsy-focused educational website, Epilog.us [http://www.Epilog.us], now features a panel discussion of leading experts on the role of rational polytherapy in the treatment of patients with epilepsy, led by Dr. Barry Gidal, Professor of Pharmacy and Neurology/Division Chair, University of Wisconsin. Dr. Gidal also brings forward discussion on the mechanism of action of specific antiepileptic drugs (AEDs). Additional topics include: AED pharmacokinetics; patient adherence and AEDs; and drug interactions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59891-upsher-smith-epilog-us-pharmacodynamics-of-antiepileptic-drugs-aeds
Interim clinical results from Project IMPACT: Diabetes, announced today by the American Pharmacists Association (APhA) Foundation, show statistically significant decreases in A1C or blood sugar levels, LDL cholesterol, systolic blood pressure and Body Mass Index (BMI), which are all recognized standards of diabetes care. Participating patients in 25 communities who experienced improved outcomes encompass almost every socioeconomic class, insurance status and ethnicity.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62268-american-pharmacists-association-apha-foundation-project-impact-diabetes
Diabetes experts met and determined that some self-monitoring blood glucose (SMBG) systems, despite meeting accuracy standards at the time of U.S. Food and Drug Administration (FDA) clearance, fail to consistently meet accuracy standards once on the market, potentially putting patient health at risk. In a public meeting convened by the Diabetes Technology Society on May 21, 2013, in Arlington, Virginia, leading academic clinicians, clinical chemists, medical device experts, patient advocates and FDA representatives reviewed a growing body of peer-reviewed research demonstrating that the performance of some blood glucose monitors on the market may not be meeting accuracy standards.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/61870-diabetes-technology-society-inaccurate-blood-glucose-monitors-risky
